114 related articles for article (PubMed ID: 15182731)
1. AM3 inhibits HBV replication through activation of peripheral blood mononuclear cells.
Majano P; Roda-Navarro P; Alonso-Lebrero JL; Brieva A; Casal C; Pivel JP; López-Cabrera M; Moreno-Otero R
Int Immunopharmacol; 2004 Jul; 4(7):921-7. PubMed ID: 15182731
[TBL] [Abstract][Full Text] [Related]
2. Antiviral effect of Curcuma longa Linn extract against hepatitis B virus replication.
Kim HJ; Yoo HS; Kim JC; Park CS; Choi MS; Kim M; Choi H; Min JS; Kim YS; Yoon SW; Ahn JK
J Ethnopharmacol; 2009 Jul; 124(2):189-96. PubMed ID: 19409970
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of HMGN2 protein on human hepatitis B virus expression and replication in the HepG2.2.15 cell line.
Feng Y; He F; Zhang P; Wu Q; Huang N; Tang H; Kong X; Li Y; Lu J; Chen Q; Wang B
Antiviral Res; 2009 Mar; 81(3):277-82. PubMed ID: 19150374
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro.
Vincent IE; Lucifora J; Durantel D; Hantz O; Chemin I; Zoulim F; Trepo C
Antivir Ther; 2009; 14(1):131-5. PubMed ID: 19320247
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic response of chronic active hepatitis B (CAHB) to a new immunomodulator: AM3. Immunohematological effects.
Villarrubia VG; Valladolid JM; Elorza FL; Sada G; Vilchez JG; Jimenez M; Herrerias JM
Immunopharmacol Immunotoxicol; 1992; 14(1-2):141-64. PubMed ID: 1597653
[TBL] [Abstract][Full Text] [Related]
6. [Study on inhibitory effect of CpG-ODN on HBV replication in vitro].
Li N; Fan XG; Chen ZH; Zhu C
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Jan; 21(1):103-5. PubMed ID: 15629096
[TBL] [Abstract][Full Text] [Related]
7. RNA interference inhibits hepatitis B virus gene expression and replication in HepG2-N10 cells.
Ren JL; Pan JS; Cheng T; Dong J; Lu YP; Huang SJ; Shi HX; Wang L; Lian YM
Chin J Dig Dis; 2006; 7(4):230-6. PubMed ID: 17054586
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the hepatitis B virus replication in vitro by an oligodeoxynucleotide containing cytidine-guanosine motifs.
Li N; Fan XG; Chen ZH; Zhu C; Liu HB; Huang Y
Immunol Lett; 2006 Jan; 102(1):60-6. PubMed ID: 16105691
[TBL] [Abstract][Full Text] [Related]
9. Antiviral effect of Phyllanthus nanus ethanolic extract against hepatitis B virus (HBV) by expression microarray analysis.
Lam WY; Leung KT; Law PT; Lee SM; Chan HL; Fung KP; Ooi VE; Waye MM
J Cell Biochem; 2006 Mar; 97(4):795-812. PubMed ID: 16237706
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication.
Yang J; Bo XC; Ding XR; Dai JM; Zhang ML; Wang XH; Wang SQ
J Viral Hepat; 2006 Mar; 13(3):158-65. PubMed ID: 16475991
[TBL] [Abstract][Full Text] [Related]
11. The immunosenescent phenotype in mice and humans can be defined by alterations in the natural immunity reversal by immunomodulation with oral AM3.
Villarrubia VG; Moreno Koch MC; Calvo C; González S; Alvarez-Mon M
Immunopharmacol Immunotoxicol; 1997 Feb; 19(1):53-74. PubMed ID: 9049659
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of hepatitis B virus polymerase-activity by various agents. Transient expression of hepatitis B virus DNA in hepatoma cells as novel system for evaluation of antiviral drugs.
Galle PR; Theilmann L
Arzneimittelforschung; 1990 Dec; 40(12):1380-2. PubMed ID: 2095136
[TBL] [Abstract][Full Text] [Related]
13. Whole genome expression profiling of hepatitis B virus-transfected cell line reveals the potential targets of anti-HBV drugs.
Ding XR; Yang J; Sun DC; Lou SK; Wang SQ
Pharmacogenomics J; 2008 Feb; 8(1):61-70. PubMed ID: 17505500
[TBL] [Abstract][Full Text] [Related]
14. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro.
McMillan JS; Shaw T; Angus PW; Locarnini SA
Hepatology; 1995 Jul; 22(1):36-43. PubMed ID: 7601429
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of multiple gene expression and virus replication of HBV by stable RNA interference in 2.2.15 cells.
Ren X; Luo G; Xie Z; Zhou L; Kong X; Xu A
J Hepatol; 2006 Apr; 44(4):663-70. PubMed ID: 16466826
[TBL] [Abstract][Full Text] [Related]
16. The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging.
Feld JJ; Colledge D; Sozzi V; Edwards R; Littlejohn M; Locarnini SA
Antiviral Res; 2007 Nov; 76(2):168-77. PubMed ID: 17709147
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy of siRNAs mediates greater suppression on hepatitis B virus cccDNA in HepG2.2.15 cell.
Xin XM; Li GQ; Guan XR; Li D; Xu WZ; Jin YY; Gu HX
Hepatogastroenterology; 2008; 55(88):2178-83. PubMed ID: 19260501
[TBL] [Abstract][Full Text] [Related]
18. The short hairpin RNA driven by polymerase II suppresses both wild-type and lamivudine-resistant hepatitis B virus strains.
Ren GL; Fang Y; Ma HH; Lei YF; Wang D; Xu MC; Wang PZ; Huang CX; Nie OH; Sun YT; Bai XF
Antivir Ther; 2007; 12(6):865-76. PubMed ID: 17926641
[TBL] [Abstract][Full Text] [Related]
19. In vitro resistance to interferon-alpha of hepatitis B virus with basic core promoter double mutation.
Wang Y; Wei L; Jiang D; Cong X; Fei R; Chen H; Xiao J; Wang Y
Antiviral Res; 2007 Aug; 75(2):139-45. PubMed ID: 17397939
[TBL] [Abstract][Full Text] [Related]
20. [Synthesis of a novel L-nucleoside, beta-L-D4A and its inhibition on the replication of hepatitis B virus in vitro].
Wu JM; Lin JS; Xie N; Qiu GF; Hu XM
Yao Xue Xue Bao; 2005 Sep; 40(9):825-9. PubMed ID: 16342685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
